Skip to main content
Signal8

Karyopharm Therapeutics Inc. (KPTI)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

OTC:KPTIOTC (suspended from Nasdaq on Nov 11, 2026)Sub-class of KPTIQHealthcare
Mkt Cap$395K
EV-
Float21.53M
O/S22.68M
VOL146.51M sh
$ Vol$5.23M
RVOL5.19×
Inst Own76.4%
SI38.2%
Net Cash/Sh-
Dilution
Karyopharm Therapeutics Inc. logoOTC:KPTI
Historical Data
DateOpenHighLowCloseVolume
Nov 10, 20260.02920.02990.01700.0174146,821,550
Nov 9, 20260.04400.04420.03500.040023,722,491
Nov 6, 20260.04760.05580.04010.0549104,537,598
Nov 5, 20260.05390.06430.05010.060118,847,981
Nov 4, 20260.08100.12740.07290.072940,915,199
Nov 3, 20260.11000.11000.08200.088316,868,113
Nov 2, 20260.15300.16000.09460.112047,445,500
Oct 30, 20260.90200.90200.58420.66203,523,426
Oct 29, 20260.80970.98690.78070.87986,845,525
Oct 28, 20260.45600.90910.45600.832155,288,020
Oct 27, 20260.45920.48290.43040.4800996,614
Oct 26, 20260.50840.51660.42240.48211,365,207
Oct 23, 20260.53660.55500.44000.51751,963,966
Oct 22, 20260.43700.55260.42220.54617,488,473
Oct 21, 20260.36300.43600.36300.42441,616,516
Oct 20, 20260.34000.38920.34000.3586766,733
Oct 19, 20260.40000.40000.33110.34601,258,369
Oct 16, 20260.35090.40000.33000.39012,708,532
Oct 15, 20260.31000.35220.31000.35081,399,094
Oct 14, 20260.42740.42740.31500.31502,075,539
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
13
HOLD
6
SELL
2
TOTAL21
Insider Trades
InsiderTypeShares
Abate Kristin profile photoAbate KristinSale4.8K
Abate Kristin profile photoAbate KristinSale378
Abate Kristin profile photoAbate KristinSale19
Poulton Stuart profile photoPoulton StuartSale189
Schor Chen profile photoSchor ChenGrant/Award15.5K
Oliger Christy J. profile photoOliger Christy J.Grant/Award15.5K
Shareholders
76.4%
Institutional
(92)
0.0%
Insiderⓘ
(0)
0.0%
5%+ Owners
(0)
23.6%
Unattributed (incl. retail)ⓘ
Institutional76.4%
Unattributed (incl. retail)23.6%
Sources: 13FO/S: 22.7M · as of 6 Aug 2026 · SEC filings
Insiders & Institutional Holders
About

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.

The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors.

In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. On November 2, 2026, Karyopharm Therapeutics Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Key Metrics
Market Cap$394,657
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership76.39%

based on 22.68M shares outstanding

SectorHealthcare
IndustryMedical - Pharmaceuticals
ExchangeOTC
CountryUSUS
IPO DateNov 6, 2013
Shares Outstanding22.68M
Authorized Shares
Float21.53M
SEC Float (non-affiliate)22.56M
52-Week Range
Volume
Average Daily Volume28.25M

30d Avg

28.25M

60d Avg

13.77M

90d Avg

9.28M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of KPTI as of Jun 30, 2026 records an effective S-3 shelf registration (effective May 14, 2026), an at-the-market sales agreement dated Feb 17, 2023, 7 outstanding warrant series and a PIPE closed Mar 26, 2026, from SEC filings. 1 insider reported 3 open-market sales of KPTI stock on Form 4 in the 90 days to Nov 17, 2026. Karyopharm Therapeutics Inc. (OTC: KPTI) is in the Healthcare sector (Medical - Pharmaceuticals).